IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 901-925 out of 1382.

<< < 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 > >>

Public Release: 28-Apr-2016
JAMA Oncology
Costs for orally administered cancer drugs skyrocket
New cancer drugs, taken in pill form, have become dramatically more expensive in their first year on the market compared with drugs launched 15 years ago, calling into question the sustainability of a system that sets high prices at market entry in addition to rapidly increasing those prices over time.

Contact: Thania Benios
thania_benios@unc.edu
919-962-8596
University of North Carolina at Chapel Hill

Public Release: 28-Apr-2016
JAMA Oncology
Recent cancer diagnosis associated with increased risk of mental health disorders
A recent cancer diagnosis was associated with increased risk for some mental health disorders and increased use of psychiatric medications, according to a new study published online by JAMA Oncology that used data from Swedish population and health registers.

Contact: Donghao Lu, M.D.
donghao.lu@ki.se
The JAMA Network Journals

Public Release: 28-Apr-2016
European Urology
Narrow band imaging can reduce recurrence of bladder tumors
Research into bladder tumor surgery has found that using narrow band imaging can significantly reduce the risk of disease recurrence.

Contact: Luke Harrison
l.harrison.1@bham.ac.uk
University of Birmingham

Public Release: 28-Apr-2016
Cancer
HPV vaccination expected to reduce cancer in all races, may not eliminate all disparities
Human papillomavirus (HPV)-associated cancers occur more frequently among Hispanics, blacks, American-Indians, and Alaska Natives than among whites. A new study from Harvard T.H. Chan School of Public Health finds that HPV vaccination is expected to reduce the cancer burden across all racial/ethnic groups. However, some disparities in cancer burden may persist and widen in the years to come if their causes, such as lack of access to diagnoses and treatment, aren't addressed.
NIH/National Cancer Institute

Contact: Marge Dwyer
mhdwyer@hsph.harvard.edu
617-432-8416
Harvard T.H. Chan School of Public Health

Public Release: 28-Apr-2016
Cell Reports
A new discovery in the fight against cancer: Tumor cells switch to a different mode
When medication is used to shut off the oxygen supply to tumor cells, the cells adapt their metabolism in the medium term -- by switching over to producing energy without oxygen. This observation by biomedical scientists at the University of Basel and University Hospital Basel could be used for treatments that can inhibit tumor growth in the long term, as the researchers report in the latest issue of the journal Cell Reports.

Contact: Yannik Sprecher
yannik.sprecher@unibas.ch
41-612-672-424
University of Basel

Public Release: 28-Apr-2016
Molecular Systems Biology
Scientists predict cell changes that affect breast cancer growth
Using a broad spectrum of analytical tools, scientists from the Florida campus of the Scripps Research Institute have shown how sometimes small, often practically imperceptible, structural changes in a key breast cancer receptor are directly linked to regulating molecules and can produce predictable effects in curbing or accelerating cancer growth.
National Institutes of Health, Frenchman's Creek Women for Cancer Research, BallenIsles Men's Golf Association, National Science Foundation, National Science Foundation of China, Key Project of Ministry of Education, and others

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute

Public Release: 28-Apr-2016
Cancer Cell
TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by the University of Texas MD Anderson Cancer Center.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 28-Apr-2016
Environmental Research
Study links residential radon exposure to hematologic cancers in women
A new report finds a statistically-significant, positive association between high levels of residential radon and the risk of hematologic (blood) cancer in women.
American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 27-Apr-2016
Nature
Scientists uncover new way to grow rare life-saving blood stem cells
A protein called Musashi-2 regulates the function and development of important blood stem cells. This knowledge provides new strategies that can be used to control the growth of these cells -- cells that can be used as therapeutics for a range of life-threatening diseases but are, in general, in very short supply.
Ontario Institute for Cancer Research, Canadian Institutes of Health Research, Canadian Blood Services, Health Canada, National Institutes of Health, California Institute for Regenerative Medicine

Contact: Veronica McGuire
vmcguir@mcmaster.ca
905-525-9140 x22169
McMaster University

Public Release: 27-Apr-2016
Oncotarget
Breast cancer progression -- the devil is in the detail
Researchers at Helmholtz Zentrum München describe how breast cancer cells challenged with a small-molecule inhibitor targeting specific invasive properties switch to an alternative mode-of-action, rendering them even more aggressive. The results may impair future therapeutic approaches in the TGF-beta pathway and are published in the journal Oncotarget.
German Cancer Aid Foundation

Contact: Dr. Christina Scheel
christina.scheel@helmholtz-muenchen.de
49-893-187-2012
Helmholtz Zentrum München - German Research Center for Environmental Health

Public Release: 27-Apr-2016
Journal of Clinical Investigation
Study: 93 percent of advanced leukemia patients in remission after immunotherapy
Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (disease-fighting immune cells) were genetically engineered to fight their cancers. This study is the first CAR T-cell trial to infuse patients with an even mixture of two types of T cells (helper and killer cells, which work together to kill cancer).
NIH/National Cancer Institute, Juno Therapeutics, Life Sciences Discovery Fund, and others

Contact: Sandy Van
svan2@fredhutch.org
808-526-1708
Fred Hutchinson Cancer Research Center

Public Release: 27-Apr-2016
Urology
New model for active surveillance of prostate cancer tested
Urologists at University of California, San Diego School of Medicine and Genesis Healthcare Partners have tested a new model of care for patients with low-risk prostate cancer. The evidence-based approach uses best practices to appropriately select and follow patients to avoid disease overtreatment. Results of the three-year study are now published online in the journal of Urology.

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 26-Apr-2016
JAMA
Poor understandability of notifications sent to women regarding breast density
In a study appearing in the April 26 issue of JAMA, Nancy R. Kressin, Ph.D., of the Veterans Affairs Boston Healthcare System, Boston University School of Medicine, and colleagues examined the content, readability, and understandability of dense breast notifications sent to women following screening mammography.

Contact: Gina DiGravio-Wilczewski
ginad@bu.edu
The JAMA Network Journals

Public Release: 26-Apr-2016
Nature Communications
MicroRNA pathway could lead to new avenues for leukemia treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow. These findings are being published in the April 26 issue of the online journal Nature Communications.
Leukemia and Lymphoma Society, National Institutes of Health, American Cancer Society, University of Chicago Committee on Cancer Biology Fellowship Program, LLS Special Fellowship

Contact: Katie Pence
pencekatie@yahoo.com
513-558-4561
University of Cincinnati Academic Health Center

Public Release: 26-Apr-2016
JAMA
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A. Rafferty, M.D., formerly of Massachusetts General Hospital, Boston, and colleagues evaluated the screening performance of digital mammography combined with tomosynthesis (a type of imaging) compared with digital mammography alone for women with varying levels of breast density.

Contact: Kathy Weiner
lmradkat@verizon.net
The JAMA Network Journals

Public Release: 26-Apr-2016
JAMA
Study finds readability of dense breast notifications poor
About half of American women have dense breasts, which makes it harder for mammograms to identify cancer and add to a woman's risk for cancer. Nearly half of US states have passed legislation requiring women to be notified of their breast density when they receive mammogram results, despite no scientific evidence or guidelines for appropriate care for women with dense breasts.

Contact: Gina DiGravio
ginad@bu.edu
617-638-8480
Boston University Medical Center

Public Release: 26-Apr-2016
PLOS Medicine
New hepatocellular carcinoma prognostic model improves prediction of patient survival
The ITA.LI.CA prognostic system, a model integrating tumor staging, liver function, functional status, and alpha-fetoprotein level, builds on previous models of hepatocellular carcinoma (HCC) prognosis and shows superior survival prediction in Italian and Taiwanese cohorts, according to a study published this week in PLOS Medicine by Alessandro Vitale of Azienda Ospedaliera Universitaria di Padova, Italy, and colleagues.

Contact: PLOS Medicine
medicinepress@plos.org
PLOS

Public Release: 26-Apr-2016
Biophysical Journal
How breast cancer cells slide to metastasis
The spreading of cancer cells from one part of the body to another, a process known as metastasis, is the leading cause of death among cancer patients. A study published April 26 in Biophysical Journal now reveals why some cancer cells may be more metastatic than others. The findings show that breast cancer cells spread to other parts of the body by sliding around other cells blocking their escape route out of the original tumor.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 26-Apr-2016
Journal of Nanobiotechnology
Danish researchers behind vaccine breakthrough
A Danish research team from the University of Copenhagen has designed a simple technique that makes it possible to quickly and easily develop a new type of vaccines. The simple and effective technique will pave the way for effective vaccines against not only infectious diseases but also cancer and other chronic diseases.

Contact: Adam Sander
asander@sund.ku.dk
45-30-11-15-29
University of Copenhagen The Faculty of Health and Medical Sciences

Public Release: 26-Apr-2016
PLOS Medicine
Cholesterol levels, not statins, influence colorectal cancer risk
Long-term use of the cholesterol-lowering drugs known as statins does not appear to decrease a patient's risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine researchers published this week in PLOS Medicine.
NIH/National Cancer Institute

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine

Public Release: 26-Apr-2016
Hepatology
Aspirin may help prevent bile duct cancer
Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 26-Apr-2016
Journal of Urology
Researchers look for causes of unexpected early bladder cancer recurrence after laparoscopic surgery
Although laparoscopic radical cystectomy (LRC) and robotic assisted radical cystectomy (RARC) continue to grow in popularity and are successful in the treatment of bladder cancer, they are still considered experimental approaches. Using data collected by the Section of Uro-Technology of the European Association of Urology, a team of researchers found that about 5 percent of patients experienced unexpected relapses of cancer after LRC, even with favorable pathology. Their results are reported in The Journal of Urology®.

Contact: Eileen Leahy
jumedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 26-Apr-2016
Addiction
Caution advised in over-regulating e-cigarettes as alternative to smoking tobacco
International tobacco control experts compared the potential risks of e-cigarette use with the benefit of use in aiding smoking cessation, advising regulators to balance the risk-reward of e-cigarette use as a tool in smoking cessation.
US Food and Drug Administration, NIH/National Institute on Drug Abuse

Contact: Allison Leggett
leggett@musc.edu
843-323-9064
Medical University of South Carolina

Public Release: 26-Apr-2016
eLife
Scientists provide new insights into gene regulation
Researchers at the University of Leicester have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Wellcome Trust, Biotechnology and Biological Sciences Research Council, Royal Society

Contact: Professor John Schwabe
john.schwabe@le.ac.uk
01-162-297-030
University of Leicester

Public Release: 26-Apr-2016
eLife
Oscillations determine whether blood vessels grow thicker or branch
How do the cells of blood vessels decide between growing new side branches or expanding the surface? A new publication in eLife explains the mechanism and shows how the cells can behave as a collective, moving in the same direction together during blood vessel growth. The cells communicate using signals that exhibit oscillating patterns, as the scientists discovered using a combination of computer simulations and experiments. The findings are significant for diabetes and cancer.
Cancer Research UK, Lister Institute of Preventive Medicine, Leducq Transatlantic Network ARTEMIS, European Research Council

Contact: Vera Glaßer
vera.glasser@mdc-berlin.de
49-309-406-2120
Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Showing releases 901-925 out of 1382.

<< < 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 > >>

  Search News Releases

     

 

EurekAlert!